DE2703964A1 - Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis - Google Patents

Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis

Info

Publication number
DE2703964A1
DE2703964A1 DE19772703964 DE2703964A DE2703964A1 DE 2703964 A1 DE2703964 A1 DE 2703964A1 DE 19772703964 DE19772703964 DE 19772703964 DE 2703964 A DE2703964 A DE 2703964A DE 2703964 A1 DE2703964 A1 DE 2703964A1
Authority
DE
Germany
Prior art keywords
fumaric acid
glycine
psoriasis
parts
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19772703964
Other languages
German (de)
Inventor
Walter Dr Schweckendiek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19752530372 external-priority patent/DE2530372A1/en
Application filed by Individual filed Critical Individual
Priority to DE19772703964 priority Critical patent/DE2703964A1/en
Publication of DE2703964A1 publication Critical patent/DE2703964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical prepn. (I) for the treatment of psoriasis, comprises fumaric acid, its neutral- and acid salts, di- and mono esters or their salts, including manganese salts, admixed with glycine and opt. sec. phosphate such as CaHPO4 for internal and external application. (I) have a very broad spectrum of activity. The additives ensure excellent compatibility in the gastric- and digestive tract upon oral admin.; they prevent flush. They also prevent inflammatory erythema and itching of the skin upon external application.

Description

Parmazeutische Zubereitungen zur Behandlung von PSORIASISPharmaceutical preparations for the treatment of PSORIASIS

In der Offenlegungsschrift 2.530.372/Seite 2, Aktenzeichen P 2.530.372.4-41, Anmeldetag: 08.07.75, Offenlegungstag: 13.01.77, wurde erwähnt, daß bei Psoriasis der Glycinstoffwechsel gestört sei (vgl. auch Medizin heute (19) 170/S. 10 - 12 sowie "Arztliche Praxis" (23) 1971/S. 10.34). Ferner wurde 1968 auf eine enge Beziehung zum Phosphatasensystem aufmerksam gemacht (Selecta 1968/Nr 38/S VIII).In the Offenlegungsschrift 2.530.372 / page 2, file number P 2.530.372.4-41, Filing date: 07/08/75, disclosure date: 01/13/77, it was mentioned that in psoriasis the glycine metabolism is disturbed (see also Medicine Today (19) 170 / p. 10 - 12 as well as "Arztliche Praxis" (23) 1971 / S. 10.34). Furthermore, 1968 was on a close relationship Attention was drawn to the phosphatase system (Selecta 1968 / Nr 38 / S VIII).

Uie in der obengenannten uffenlegungsschrift beschriebene Benandlungsmethode konnte nun perfektioniert werden unter Einbeziehung der externen und internen Applikation von GLYCIN.The treatment method described in the abovementioned publication could now be perfected with the inclusion of the external and internal application by GLYCIN.

Auf die Bedeutung des Glycinanteils in der Haut (Kollagen) wurde wiederholt hingewiesen, wie schon gesagt wurde. Nicht nur Glycin, sondern auch Asparaginsäure fehlen in den Schuppen der Psoriatiker (s. Offenlegungsschrift 2.530.372/S 2). uie Aminosäurensequenz des Kollagens von Psoriatikern ist also gestört, andernfalls würde es nicht zur entarteten Schuppenbildung in diesem Ausmasse kommen können. Uer Glycinanteil in der gesunden Haut betrugt immerhin 30 X, der von Asparaginsäure etwa 6 X. Es lag daher nahe, bei PSORIASIS Glycin extern und intern zu applizieren, und es ist erstaunlich, daß diese Applikation daher unterblieben ist. Rein tneoretisch sind via Fumarsäureverbindungen beiacminosäuren in vivo synthetisierbar. Aus Fumarsäure entsteht durch Oxydation leicht OXALESSIGSAURE. Durch Ammoniakanlagerung an die Enolform der Oxalessigsäure entsteht theoretisch B-Hydroxy-Asparaginsäure, durch Uecarboxylierung Serin, aus Serin bekanntlich GLYCIN.The importance of the glycine content in the skin (collagen) was repeated pointed out, as has already been said. Not just glycine, but aspartic acid as well are absent in the scales of psoriatic people (see Offenlegungsschrift 2.530.372 / S 2). uie So the amino acid sequence of the collagen of psoriasis is disturbed, otherwise it would not be possible for degenerate scale formation to this extent. The proportion of glycine in healthy skin was at least 30%, that of aspartic acid about 6 X. It was therefore obvious to apply glycine externally and internally with PSORIASIS, and it is astonishing that this application has therefore not been carried out. Purely theoretically can be synthesized in vivo with acmino acids via fumaric acid compounds. From fumaric acid easily formed by oxidation. By ammonia deposition to the Theoretically, the enol form of oxaloacetic acid is formed by B-hydroxy aspartic acid Uecarboxylation Serine, from serine known as GLYCINE.

Aus Oxalessigsäure entsteht durch Transaminierung auch Asparaginsäure.Aspartic acid is also formed from oxaloacetic acid through transamination.

Bei gestörtem GLYCIN-Stoffwechsel empfiehlt es sich daher, Glycin extern und intern zuzuführen, was bisher nicht bekannt war. Bekannt sind nur externe Zubereitungen, die z. B. ALLANTOIN enthalten. Allantoin ist ein inneres Salz der DI-UREIDO-ESSIGSSURE.If the GLYCIN metabolism is disturbed, it is therefore recommended to use glycine to be supplied externally and internally, which was previously unknown. Only external ones are known Preparations that z. B. ALLANTOIN included. Allantoin is an inner salt of the DI-UREIDO-ESSIGSSURE.

Es wurde nun gefunden, daß man Psoriasis mit Fumarsäureverbindungen unter Zusatz von GLYCIN sehr erfolgreich behandeln kann unter Ausscnaltung störender Begleitersciieinungen. üie Anwesenheit von Phosphaten, wie z. B. von Calcium-phosphor.ium (CaHPO ), ist dabei manchmal vorteilhaft. Als Verdünnungspulver V.U. fungiert (gemäß Offenlegungsschrift 2.530.372/5 1) in diesem Fall ein Gemisch von Glycin und sekundären Phosphaten. In manchen Fällen genügt allein GLYCIN als Verdünnungspulver bzw als Zusatzkomponente.It has now been found that psoriasis can be treated with fumaric acid compounds with the addition of GLYCIN can treat very successfully by eliminating disturbing Accompanying instructions. üie presence of phosphates, such as. B. from Calcium-phosphor.ium (CaHPO), is sometimes beneficial. As a thinning powder V.U. acts (according to Offenlegungsschrift 2.530.372 / 5 1) in this case a mixture of glycine and secondary Phosphates. In some cases, GLYCIN alone is sufficient as a diluent or as a Additional component.

Uie neuen pharmazeutischen Zubereitungen haben ein sehr breites Wirkungsspektrum. uie Zusätze garantieren eine ausgezeichnete Verträglichkeit im rlagen-Darmtrakt oei interner Applikation und verhindern bei externer anwendung entzündliche Erytheme und Juckreiz auf der Haut weitgehendst.The new pharmaceutical preparations have a very broad spectrum of activity. uie additives guarantee excellent tolerance in the gastrointestinal tract o for internal application and prevent inflammatory erythema with external application and itching of the skin to a large extent.

Beispiel 1 ORALE ZUBEREITUNG adan mischt z. 8. 10 Teile der Fumarsäuregemische 2, 3 oder 4 der Offenlegungsschrift 2.530.372 mit 10 Teilen GLYCIN und verabreicht dieses gemisch in 0,5 can Gelatinekapseln (dünndarmlöslich). Dosierung: 1 - 2 Kapseln pro Tag zum Frühstück oder Abendbrot mit etwas Flüssigkeit.Example 1 ORAL PREPARATION adan mixes z. 8. 10 parts of the fumaric acid mixtures 2, 3 or 4 of laid-open specification 2.530.372 with 10 parts of GLYCIN and administered this mixture in 0.5 can gelatine capsules (soluble in the small intestine). Dosage: 1 - 2 capsules per day for breakfast or dinner with a little liquid.

Kapseln: "CAPSULAE OPERCULATAE" der Firma Pohl und Boskamp, Hohenlochstedt/Holstein.Capsules: "CAPSULAE OPERCULATAE" from Pohl and Boskamp, Hohenlochstedt / Holstein.

Gegebenenfalls mischt man z. B. 10 Teile der obengenannten Beispiele 2, 3 oder 4 mit 10 Teilen GLYCIN und 2 Teilen CaHPO (Calcium phosphoricum).If necessary, mix z. B. 10 parts of the above examples 2, 3 or 4 with 10 parts GLYCIN and 2 parts CaHPO (Calcium phosphoricum).

Natürlicn kann man auch 100 - 300 mg der Beispiele 2, 3 oder 4 der Offenlegungsschrift 2.530.372 direkt, in Kapseln abgefüllt, daneben Glycin, in Kapseln abgefüllt, als Einzeldosierungen unabhängig voneinander applizieren mit etwas Flüssigkeit. Dasselbe gilt für CaHPO4.Of course, 100-300 mg of Examples 2, 3 or 4 can also be used Offenlegungsschrift 2.530.372 directly, filled into capsules, next to glycine, in capsules Bottled, apply as single doses independently of each other with a little liquid. The same is true for CaHPO4.

Z. B. 200 mg Beispiel 4 in 0,5 ccm Kapsel (aus Gelatine) 500 mg GLYCIN in 0,5 ccm Kapsel (aus Gelatine) 150 mg CaHP04 in 0,5 ccm Kapsel (aus Gelatine).E.g. 200 mg of example 4 in 0.5 cc capsule (made of gelatine) 500 mg GLYCIN in 0.5 ccm capsule (made from gelatine) 150 mg CaHPO4 in 0.5 ccm capsule (made from gelatine).

Das Einnehmen der Fumarsäuregemische in Kombination mit GLYCIN ist sehr gut verträglicn, Beschwerden im lXagen-Uarmtrakt treten nicht auf. Auch wird ein sogenannter FLUSH vermieden, der manchen Patienten unangenehm ist.Taking the fumaric acid mixture in combination with GLYCIN is Very well tolerated, there are no complaints in the LXagen urinary tract. Also will Avoid a so-called FLUSH, which is uncomfortable for some patients.

Beispiel 2 SALBE F0R EXTERNE APPLIKATIüN 8 Teile GLYCIN werden in 42 Teilen Wasser weitgehend gelöst und mit 40 Teilen Eucerin (wasserfrei) unter Zusatz von weiteren 10 Teilen Wasser zu einer Salbe homogener Konsistenz angepastet.EXAMPLE 2 Ointment FOR EXTERNAL APPLICATION 8 parts of GLYCINE are in 42 parts of water largely dissolved and mixed with 40 parts of Eucerin (anhydrous) Addition of another 10 parts of water pasted to an ointment of homogeneous consistency.

Die Salbe hat einen pH-Wert von ca. 7 und ist ausgezeichnet verträglich und hautschonend.The ointment has a pH value of approx. 7 and is extremely well tolerated and gentle on the skin.

Beispiel 3 SALBE FÜR EXTERNE APPLIKATION 6 Teile Glycin und 6 Teile Fumarsäure werden unter Zusatz von 2 Teilen CaHPO . 2 H O und von 56 Teilen Eucerin (wasserfrei) mit ca. 30 Teilen Wasser zu einer Salbe homogener Konsistenz verrührt. Diese Salbe reagiert auf der Haut schwach sauer und ist sehr gut verträglich.Example 3 Ointment FOR EXTERNAL APPLICATION 6 parts glycine and 6 parts Fumaric acid with the addition of 2 parts of CaHPO. 2 HO and from 56 parts of Eucerin (anhydrous) mixed with approx. 30 parts of water to form an ointment of homogeneous consistency. This ointment reacts slightly acidic on the skin and is very well tolerated.

Beispiel 4 SALBE FOR EXTERNE APPLIKATION 2 Teile Salicylsäure, 2 Teile Mangansalz des Fumarsäuremonoäthylesters, z Teile Zinksalz des Fumarsäuremonoäthylesters, 2 Teile Fumarsäure, T Teil Fumarsäuremonoäthylester, 1 Teil Fumarsäuredimethylester werden mit 1 - 3 Teilen GLYCIN und 5 Teigen CaHPU4 . 2 H O in 30 Teilen Wasser suspendiert und mit 60 - 70 Teilen Eucerin (wassePfrei) unter Zusatz von weiteren 10 Teilen Wasser zu einer homogenen, sämigen Salbe gewünschter Konsistenz angepastet.Example 4 Ointment FOR EXTERNAL APPLICATION 2 parts salicylic acid, 2 parts Manganese salt of fumaric acid monoethyl ester, z parts of zinc salt of fumaric acid monoethyl ester, 2 parts of fumaric acid, T part of monoethyl fumarate, 1 part of dimethyl fumarate are made with 1 - 3 parts GLYCIN and 5 doughs CaHPU4. 2 HO suspended in 30 parts of water and with 60 - 70 parts of Eucerin (water-free) with the addition of a further 10 parts Water pasted to a homogeneous, creamy ointment of the desired consistency.

Die Salbe reagiert auf der Haut sauer und wird im allgemeinen sehr gut vertragen. Gegebenenfalls schwächt man sie mit 70 Xigem EUCERIN ab (70 X Eucerin, 30 X Wasser).The ointment is acidic on the skin and in general becomes very well tolerated. If necessary, they are weakened with 70% EUCERIN (70% Eucerin, 30 X water).

Beispiel 5 LOTION für Haut und speziell für Kopfhaut (externe Applikation) 4 Teile GLYCIN, 3 Teile Fumarsäure, 8 Teile Glycerin, 25 Teile isopropyl alkohol, 60 Teile Wasser werden vermischt und kurz auf 70 - 80 C erhitzt.Example 5 LOTION for skin and especially for scalp (external application) 4 parts GLYCIN, 3 parts fumaric acid, 8 parts glycerin, 25 parts isopropyl alcohol, 60 parts of water are mixed and briefly heated to 70 - 80 C.

Nach dem Abkühlen erhält man eine flüssige Einstellung, die sich sehr leicht in die Haut einreiben läßt und zur Behandlung von Psoriasis auf der Kopfhaut geeignet ist. Sie reagiert schwach sauer.After cooling, you get a fluid setting that is very much Can be easily rubbed into the skin and used to treat psoriasis on the scalp suitable is. She reacts weakly angry.

Claims (2)

PATENT - ANS P U C H 1. Leicht dosierbare pharmazeutische Zubereitungen zur Behandlung von PSORIASIS, bestehend aus Fumarsäure, ihren neutralen und sauren Salzen, ihren ui- und iXonoestern, sowie deren Salzen, einschließlich der Mangansalze, dadurch gekennzeichnet, daß man die Fumarsäureverbindungen zweckmäßig mit Glycin und gegebenenfalls mit sek. Phosphaten wie z. B. CaHPO4 intern und extern appliziert.PATENT - ANS P U C H 1. Easily metered pharmaceutical preparations for the treatment of PSORIASIS, consisting of fumaric acid, its neutral and acidic ones Salts, their ui- and iXonoesters, as well as their salts, including the manganese salts, characterized in that the fumaric acid compounds are expediently mixed with glycine and if necessary with sec. Phosphates such as B. CaHPO4 applied internally and externally. 2. Pnarmazeutische Zubereitungen zur externen Behandlung von Psoriasis auf Fumarsäurebasis, dadurch gekennzeichnet, daß man Fumarsäure und ihre Verbindungen mit Glycin zusammen, gegebenenfalls unter Zusatz von sek. Phosphaten als Salben oder in Form alkoholisch-wässriger Suspensionen oder Lösungen appliziert.2. Pharmaceutical preparations for the external treatment of psoriasis based on fumaric acid, characterized in that fumaric acid and its compounds with glycine together, optionally with the addition of sec. Phosphates as ointments or applied in the form of alcoholic-aqueous suspensions or solutions.
DE19772703964 1975-07-08 1977-02-01 Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis Pending DE2703964A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19772703964 DE2703964A1 (en) 1975-07-08 1977-02-01 Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19752530372 DE2530372A1 (en) 1975-07-08 1975-07-08 Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
DE19772703964 DE2703964A1 (en) 1975-07-08 1977-02-01 Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis

Publications (1)

Publication Number Publication Date
DE2703964A1 true DE2703964A1 (en) 1978-08-03

Family

ID=25769119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19772703964 Pending DE2703964A1 (en) 1975-07-08 1977-02-01 Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis

Country Status (1)

Country Link
DE (1) DE2703964A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004616A1 (en) * 1986-01-30 1987-08-13 Wella Aktiengesellschaft Hair processing agents and process for improving the hair condition
DE3728188A1 (en) * 1987-08-24 1989-03-09 Pearson & Co Gmbh & Co Fumaric acid esters for the external treatment of psoriasis
EP0328634A1 (en) * 1987-09-04 1989-08-23 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
WO1999013819A2 (en) * 1997-09-19 1999-03-25 E-L Management Corp. Composition and method for reducing stinging in skin
WO2004026295A2 (en) * 2002-09-17 2004-04-01 Phenion Gmbh & Co. Kg Use of skin-protecting substances
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP3508201A3 (en) * 2004-08-09 2019-10-16 Enrique Melendez Hevia Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004616A1 (en) * 1986-01-30 1987-08-13 Wella Aktiengesellschaft Hair processing agents and process for improving the hair condition
EP0234261A1 (en) * 1986-01-30 1987-09-02 Wella Aktiengesellschaft Hair-treating composition and process for improving hair condition
DE3728188A1 (en) * 1987-08-24 1989-03-09 Pearson & Co Gmbh & Co Fumaric acid esters for the external treatment of psoriasis
EP0328634A1 (en) * 1987-09-04 1989-08-23 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
EP0328634A4 (en) * 1987-09-04 1991-08-21 Dexter Biotechnics Pharmaceutical compositions for the treatment of psoriasis
WO1999013819A3 (en) * 1997-09-19 1999-06-03 E L Management Corp Composition and method for reducing stinging in skin
WO1999013819A2 (en) * 1997-09-19 1999-03-25 E-L Management Corp. Composition and method for reducing stinging in skin
WO2004026295A2 (en) * 2002-09-17 2004-04-01 Phenion Gmbh & Co. Kg Use of skin-protecting substances
WO2004026295A3 (en) * 2002-09-17 2004-11-11 Phenion Gmbh & Co Kg Use of skin-protecting substances
EP3508201A3 (en) * 2004-08-09 2019-10-16 Enrique Melendez Hevia Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof
US11052062B2 (en) 2004-10-08 2021-07-06 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
US11229619B2 (en) 2004-10-08 2022-01-25 Biogen Swiss Manufacturing Gmbh Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US11173123B2 (en) 2009-01-09 2021-11-16 Biogen Swiss Manufacturing Gmbh Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix

Similar Documents

Publication Publication Date Title
DE60225702T2 (en) STRONTIUM CONNECTION FOR THE TREATMENT OF SUB DERIVED SOFT PART PAIN
EP0206291B1 (en) Sprayable pharmaceutical preparation for topical application
DE3205504C2 (en) Topical drug containing ibuprofen
Kochakian et al. The relationship of the synthetic male hormone, androstendion, to the protein and energy metabolism of castrate dogs, and the protein metabolism of a normal dog
US3882244A (en) Method of treating acne with a c{hd 20 {b acid
DE2530372A1 (en) Oral and topical compsns. for psoriasis treatment - contg. fumaric acid (derivs.) and diluent contg. org. acid salts.
EP0185210B1 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
DE2703964A1 (en) Preparations contg. fumaric acid, glycine and opt. phosphate - for internal and external treatment of psoriasis
DE2559717A1 (en) METAL COMPOUNDS AND THEIR USES TO TREAT METAL DEFECTS
DE2639849C2 (en) Stable preparations of water-soluble salts of dehydroepiandrosterone sulfate for parenteral administration
US4915973A (en) Method for treating skin diseases
DE69329435T2 (en) Sclerosing solution
DE69526111T2 (en) COMPOSITION FOR TREATING ENDOMETRIOSE, WHICH CONTAINS A SALT OF A PRECIOUS METAL AND MEL CUM SALE
DE2221281C3 (en) Pharmaceutical preparations with anti-inflammatory and analgesic effects
DE3840744C2 (en) Activator for osteoblasts
CH677878A5 (en)
DE2011499A1 (en) Germanic acid and cysteine medicinal product and process for its manufacture
DE2901452B1 (en) Pharmaceutical preparations for the external treatment of psoriasis
DD276032A5 (en) METHOD FOR PRODUCING MEDICAMENTAL CARE FOR THE TREATMENT OF VENEER EXPANSIONS
Shils Pantothenic acid deficiency and conjugation reactions. III. Inhibitory effect of ω-methylpantothenic acid.
DE1668563C3 (en) Cer (III) -L (+) - lactate, process for its production and pharmaceutical preparations containing it
LU84952A1 (en) DRUGS WITH ANALGETIC EFFECT
DE1963326C3 (en) Process for the production of macromolecular bismuth complexes, as well as such macromolecular bismuth complexes and their use
DE821344C (en) Process for the production of water-soluble, absorbable calcium phosphates
LORDON et al. Hypoparathyroidism with hypophosphatemia: a clinical paradox due to acquired renal hyperphosphaturia

Legal Events

Date Code Title Description
OAP Request for examination filed
OD Request for examination
OHN Withdrawal